ArticleMalaria journal2022
Assessing the safety, impact and effectiveness of RTS,S/AS01
Article in Malaria journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Epidemiology Study to Assess Plasmodium Falciparum Parasite Prevalence and Malaria Control Measures in Catchment Areas of Two Interventional Studies Pre- and Post RTS,S/AS01E Introduction (EPI MAL-002 and EPI-MAL-003) to Assess, in Field Conditions, Vaccine Benefit: Risk in Children in Sub Saharan Africa
A Prospective Study to Estimate the Incidence of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Infants and Young Children in Sub-Saharan Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine
A Prospective Study to Evaluate the Safety, Effectiveness and Impact of the RTS, S/AS01E Vaccine in Young Children in Sub-Saharan Africa
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- Assessing safety in the RTS,S/AS01 malaria vaccine implementation programme: an overview and comparison of methods.Malaria journal · 2026Review
- Timing of the fourth dose of RTS,S/AS01 malaria vaccine in perennial settings: a modelling study.Malaria journal · 2026Article
- Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden.PLOS global public health · 2025Article
- The impact of the RTS,S malaria vaccine on uncomplicated malaria: evidence from the phase IV study districts, Upper East Region, Ghana, 2020-2022.Malaria journal · 2024Article
- Data Management in Multicountry Consortium Studies: The Enterics For Global Health (EFGH)Open forum infectious diseases · 2024Article
- Article
- Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report.Malaria journal · 2023Article
- Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review.Immunity, inflammation and disease · 2023Review
- Article
- Perception and awareness towards malaria vaccine policy implementation in Nigeria by health policy actors.Malaria journal · 2023Article
- Structural insights into acetylated histone ligand recognition by the BDP1 bromodomain of Plasmodium falciparum.International journal of biological macromolecules · 2022Article
- Five decades of clinical assessment of whole-sporozoite malaria vaccines.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 9 institutions in 6 countries.
Funding
Abstract
backgroundFollowing a 30-year development process, RTS,S/AS01
methodsEPI-MAL-002 (NCT02374450) is a pre-implementation safety surveillance study that is establishing the background incidence rates of protocol-defined adverse events of special interest. EPI-MAL-003 (NCT03855995) is an identically designed post-implementation safety and vaccine impact study. EPI-MAL-005 (NCT02251704) is a cross-sectional pre- and post-implementation study to measure malaria transmission intensity and monitor the use of other malaria control interventions in the study areas, and EPI-MAL-010 (EUPAS42948) will evaluate the P. falciparum genetic diversity in the periods before and after vaccine implementation.
conclusionGSK's post-approval plan has been designed to address important knowledge gaps in RTS,S/AS01
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.